KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC
Summary
This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.
Questions topics -
- Perception of Phase II mirikizumab induction data in UC
- Perception of mirikizumab’s Phase III study in UC
- Future expectations of mirikizumab in UC
- Future expectations for mirikizumab in Crohn’s disease
Key Highlights
- All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while
Read More
- Table of Contents
- Executive Summary
- Background
- Research Panel Composition
- Results & Implications
- Appendix
Read More